What A Coronary Calcium Test Can—and Can't—Tell You About Your Heart Attack Risk The way…
What are statins really doing to your body?
Many statin drug trials can’t identify statin side effects. And that means your doctor may be wrong about how safe they are.
Statin trials can hide even the most serious side effects
You might think that the more serious a side effect, the harder it is to hide. But unfortunately, that’s not true.
The most influential statin papers of the past 20 years rely on trials designed in a way that could make any side effect disappear, no matter how serious, as long as it showed up early.
This article is continued below...(scroll down)
To understand how you make side effects disappear, you first have to understand how side effects are ever determined in the first place.
How do doctors ever know what a drug is doing?
Identifying a drug’s side effects is harder than it sounds. Let me show you why.
Say you start a statin, and a few days later you wake up with mild body aches. Naturally, your mind might leap to blame the drug. But maybe you also got a flu shot a few days ago, and that could be the cause. Even if you never had problems after a flu shot before, maybe this year’s shot is different. So it’s certainly possible that it could be the flu shot and not the drug. In this scenario, your doctor would have a hard time figuring out what’s going on. The only way to know would be to stop the drug, see if the symptoms get better, then try the drug again. If the symptoms come back, it’s more likely to be the drug.
The point is, doctors don’t have any special way of knowing what’s causing your problems other than old-fashioned diagnostic thinking. We face the same puzzle our patients do when trying to assess whether statins could be causing a new set of symptoms. And, as we just saw, one of the most important variables to look at is timing.
When did the symptom start? Was it right after the drug started? Does it fade when the drug stops, and come back when it starts again?
Timing is the most basic tool we have for connecting a symptom to a cause, be it a drug or anything else. Which is why a great way to hide side effects in a drug trial is to obscure when the study really begins by calling the beginning something else. And that’s exactly what some of the largest statin trials did.
I’ll get back to how they do that in a second. But first, let’s talk about possible statin side effects.
How the statin side effects listed on the package got there
The package insert, officially called the prescribing information, is the large, many-times-folded sheet of paper that some pharmacists include with a brand-name prescription. For atorvastatin, it lists these possible side effects (the list is similar for all statins):
- Muscle damage
- Memory loss, forgetfulness, confusion and amnesia
- Depression and trouble sleeping
- Peripheral neuropathy (nerve damage)
- Fatigue
- Dizziness
- Tendon rupture
- Pancreatitis
- Lung disease
- Immune-mediated necrotizing myopathy
- Liver injury, including rare liver failure
- Higher blood sugar and increased risk of diabetes
A package insert gets its side effects from two main sources: the trials done before a drug is approved, and the reports that come in once it’s on the market.
1. Before approval: clinical trials. During the trials, researchers record every health problem anyone has, in both the drug group and the placebo group. Problems that happen more often on the drug than on placebo go into a section called “Clinical Trials Experience,” usually with percentages. The drug company drafts the label, and the FDA reviews and approves the wording.
2. After approval: real-world reports. Once millions of people are taking the drug, doctors, pharmacists and patients can report suspected side effects to the FDA through its MedWatch system. Drug companies are required to pass along any reports they receive. If a pattern emerges, it gets added to a section called “Postmarketing Experience.” These entries carry no percentages, because no one knows how many people took the drug without a problem. That’s why they’re often worded as “rare reports of…” But there’s no cutoff for using the word “rare.” For atorvastatin alone, the FDA’s database holds more than 2,000 reports of amnesia or memory impairment. And only a fraction of side effects ever get reported.
These real-world reports are incredibly helpful. Statin memory problems, for example, did not show up in trials, but they showed up in meaningful numbers afterward. The FDA received enough reports that it added them to the label in 2012.
Importantly, the authors of the most influential papers on statin side effects argue that most of these real-world reports shouldn’t be taken seriously. They are actively pushing regulators, including the FDA, to strip memory loss, depression, sleep problems and other real-world side effects from statin labels, which they call “unreliable and misleading.” Those papers are two Lancet articles: a 2016 review led by Sir Rory Collins and a 2026 analysis by the same Oxford group. Together they have shaped what most doctors believe about statin side effects. Collins built his career on research funded by hundreds of millions of pounds from drug companies, including statin makers. In today’s medical culture, that’s treated as a footnote. It should be a red flag.
Sir Collins et al’s case rests on a simple claim: people knew they were taking the drug, developed symptoms from something else, and wrongly blamed the drug.
Of course, sometimes they’re right.
So how does your doctor know?
This gets us back to the question of how to scientifically determine what side effects a drug might have. And the answer is: randomized, double-blind trials.
In these trials, volunteers are randomly assigned to take either the drug or a placebo. Nobody knows who is taking which, neither the patients nor the researchers, hence the term double-blind. It’s important that nobody knows, to prevent bias.
The bias comes from making associations, which is our natural tendency. If a person starts a drug and the next day starts getting headaches, they’re more likely to blame the drug. On the other hand, if a person starts a placebo pill and starts getting headaches the next day, they probably wouldn’t blame the placebo. This is why double-blinding a drug trial is so important.
But there’s a big problem. Two of the largest placebo-controlled statin trials, together supplying more than a quarter of all the participants in the 2026 analysis, had a hidden step that was neither randomized nor blinded. So did the two largest trials comparing high and low doses.
Let me explain.
You see, part of the trial starts before the official trial starts. That pretrial phase is called a run-in period.
Because the run-in period happens before the official trial, nobody pays attention to what happens there. But they should.
Doctors are trained to trust randomized, double-blind, placebo-controlled trials above all other evidence, and for good reason. Randomization makes the groups alike, and blinding keeps expectations from affecting the results. But a run-in period doesn’t have to be randomized or blinded. Trial designers can use it as a test period to see who tolerates statins and who develops side effects early. People who tolerate statins graduate to the next step, the double-blind, placebo-controlled phase of the study. People who don’t tolerate statins leave.

Imagine testing whether a roller coaster causes motion sickness, but first sending home everyone who got queasy on a practice ride. Your official study would find the ride remarkably safe. It would also be measuring the wrong people.
In other words, a run-in period allows statin trials to kick out people with any side effect, no matter how serious. Those who remain are the people who either don’t develop side effects, or didn’t develop them early enough to make the connection to starting the drug.
The biggest statin trial in the analysis did exactly this
The largest trial in the 2026 analysis is the Heart Protection Study (HPS). It accounts for about one in six of all participants on statins or placebo. The 2026 paper even singles it out as backing up its conclusion that statins don’t harm cognition.
Before HPS randomized anyone, every participant took simvastatin for four to six weeks, knowing it was the real drug. The investigators’ rules said that anyone who had, or even felt they had, any side effect was not to be randomized. By the time the actual trial started, more than a third of the people who began the run-in were gone.
The 2016 review admitted that this kind of run-in “may exclude some patients in whom the treatment might cause adverse effects soon after starting it.” Then it waved the concern away. It said reasons for dropping out didn’t differ between the placebo weeks and the statin weeks. But the placebo weeks always came first, and nothing about that comparison was randomized. This is the same group that tells us not to trust any evidence that isn’t randomized and blinded. When the question is whether their own trials filtered out side effects, they’re happy to rely on exactly that kind of evidence.
The 2026 paper doesn’t mention the run-in at all. It simply holds up HPS as proof that statins don’t harm cognition. That proof comes from people who had already been screened for tolerating the drug.
The truth about randomized drug trials: they’re not always randomized
Statin advocates claim that the side effects on statin labels come from unblinded or nonrandomized studies, and therefore shouldn’t count. What they don’t admit is that their own trials were unblinded at the beginning, which is when it matters most.
In my view, these trials were never designed to uncover side effects. They appear to be designed to do the exact opposite: cover them up. And then prestigious journals like the Lancet simply publish reanalyses of the same flawed data, and use them to make even stronger claims.
Statin side effects can start after a long delay, too
If you start getting weak or short of breath or slightly forgetful two years after starting a statin, how likely are you to consider that the statin might be causing your symptoms?
I can tell you this: hardly any of my patients who’ve been on a drug for several years consider that the drug they’ve been taking so long might be the cause of whatever they’re seeing me for that day, be it hives, constipation, cough, headaches, fatigue, or what have you. But just because you’ve been on a drug for years doesn’t mean you’re immune to its side effects. All of those symptoms, and many on the statin side effect list above, can start at any point.
Why this matters
Statins are among the most commonly prescribed drugs in America. Tens of millions of people take one, usually for decades. The side effects in question aren’t minor annoyances. Memory loss, confusion, depression and nerve damage can change who a person is and how they live.
Papers like these can do real harm by lulling doctors into a sense of safety. When a patient on a statin starts losing words, forgetting appointments, sleeping badly or feeling flat, a doctor who has absorbed the message that “statins don’t do that” won’t make the connection. The symptoms get blamed on age, stress or “just one of those things,” and the patient keeps taking the drug.
This isn’t abstract for me. In my own life I’ve watched people who have taken a statin for a decade or more become noticeably more cognitively impaired than their spouses, who are about the same age and don’t take statins. I can’t prove the statin caused it. But I can see what it costs the unimpaired spouse, who now spends their days watching and worrying. And I know how unlikely it is that anyone in their doctor’s office has asked whether the drug might be part of it.
Until trials are designed to catch side effects instead of screening them out, the question of what statins do to our brains is still open.
References
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026; 407: 689–703.
- Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532–61, and its supplementary appendix (webtable of trial run-in designs).
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002; 360: 7–22.
- Heart Protection Study Collaborative Group. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009; 9: 6.
- FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs (February 2012).
- Pharmacovigilance analysis of atorvastatin and memory loss in the FDA Adverse Event Reporting System. Drugs R D 2024 (link.springer.com/article/10.1007/s40268-024-00474-6).
- LIPITOR (atorvastatin calcium) prescribing information, Pfizer.
















This Post Has 0 Comments
Note: Please do not share personal information with a medical question in our comment section. Comments containing this content will be deleted due to HIPAA regulations.